Q-omics provides the consensus-scored ARHGAP16P profile across patient tissues and cancer cell-line models. ARHGAP16P expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ARHGAP16P is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, ARHGAP16P RNA expression shows 5,856 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, BRCA, and STAD as cancer lineages where ARHGAP16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP16P survival associations across molecular data types. ARHGAP16P RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP16P RNA expression–survival associations across cancer types. High ARHGAP16P expression shows unfavorable associations in SKCM, LIHC, ESCA, LUAD and LUSC, but favorable associations in BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for ARHGAP16P RNA expression.
This table summarizes ARHGAP16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGAP16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP16P shows higher tumor expression in BRCA and LUAD. The BRCA box plot shows higher ARHGAP16P RNA expression in tumor versus normal tissue (log2 FC = +0.334, t-test p < 0.001).
This table shows molecular features associated with ARHGAP16P in patient tissues and cancer cell lines. In patient samples, ARHGAP16P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
